Pharma

Sun Pharma bets on Organon front-end to drive global growth, efficiencies

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

Will AI Change Healthcare Forever? Future of India’s Pharma Shift

In this exclusive conversation with Business Standard, Sujit Paul, CEO of Zota Healthcare and the driving force behind DavaIndia, shares bold views on the future of healthcare

Cohance Lifesciences appoints Umang Vohra as chairman, CEO; Sharma exits

Pharma veteran Umang Vohra to lead Advent-backed Cohance Lifesciences as chairman and CEO, succeeding Vivek Sharma amid efforts to revive growth and address regulatory challenges

Q4 Earnings Outlook: IT, Auto, Pharma, FMCG, Metals — What to expect | Business News | Share market

India Inc heads into the Q4 FY26 earnings season navigating a complex mix of geopolitical tensions, uneven demand trends, and cost pressures.

Everstone invests $270 mn in Apothecon-Navinta specialty pharma platform

The deal creates Apothecon Group, a specialty pharma company focused on regulated markets in the US, Europe and India, with plans to expand its pipeline, footprint and acquisitions

Aurobindo Pharma sets April 12 as record date for ₹800 crore buyback

Company to repurchase up to 54.24 lakh shares at Rs 1,475 apiece through tender offer route, with promoters also eligible to participate in the buyback

Effective oversight: Safety crucial for success of weight-loss drugs

According to the National Family Health Survey 2019-21, 24 per cent of Indian women and 23 per cent of Indian men are overweight

Eli Lilly banks on tirzepatide's clinical edge as GLP-1 generics loom

Lilly positions tirzepatide as a clinically superior option as semaglutide patent expiry triggers a wave of generics, intensifying competition in India's diabetes and obesity market

Aurobindo arm launches Pomalidomide generic in US, adds to oncology line

Aurobindo Pharma subsidiary Eugia Pharma has launched generic Pomalidomide Capsules in the US, one of the first-to-file applicants for the drug, expanding its oncology portfolio

Indian MSME drugmakers likely to focus on Brazil as next growth market

India-Brazil pharma meet highlights Brazil's growing role as a priority market for Indian MSME drugmakers, driven by rising exports, regulatory engagement and demand for specialty medicines

CDSCO eases NOC norms to speed up clinical research and pharma exports

India's drug regulator is withdrawing export NOC requirements for SRA markets and easing other low-risk approvals, even as it strengthens oversight of manufacturing quality

Pharma exports rise 9.4% in FY25; industry eyes double-digit growth

The commerce ministry on Saturday said the country's pharma exports grew 9.4 per cent in 2024-25 to USD 30.47 billion and the industry is aiming for a double-digit expansion in 2026-27. Issues pertaining to pharmaceuticals exports were discussed between the government officials and industry during Chintan Shivir in Ahmedabad. The sector, currently valued around USD 60 billion, is projected to reach USD 130 billion by 2030. India ranks third globally by volume, with medicines exported to over 200 markets, and more than 60 per cent of exports destined for stringent regulatory markets. The US accounts for 34 per cent and Europe for 19 per cent of India's pharmaceutical exports. "The interaction underlined the government's focus on enabling conditions for sustained export acceleration, with industry indicating readiness to target double-digit growth in 2026-27," it said. It added that exporters were also apprised of opportunities arising from recent trade engagements with key partner

Indian pharma may face muted US growth in FY27 on gRevlimid pressure

Ind-Ra says Indian drugmakers will still see 10% revenue growth in FY27 driven by domestic demand and CDMO traction, despite weaker US sales after Revlimid expiry

Chemists warn PM that fake AI prescriptions are enabling illegal drug sales

AIOCD has urged the Prime Minister to ban AI-generated prescriptions, alleging they are being misused by unregulated e-pharmacies to sell restricted medicines, posing a serious public health risk

Uttar Pradesh govt's pharma investment kitty hits ₹38,000 crore

India's pharma market is estimated to touch $120 billion by 2030 while Uttar Pradesh accounts for roughly 17 percent of domestic sales

USV to acquire 79% stake in Wellbeing Nutrition at ₹1,583 cr valuation

USV, a pharmaceutical and biotechnology company, will acquire a 79 per cent stake in Wellbeing Nutrition at a valuation of Rs 1,583 crore. USV has signed a definitive agreement to acquire a 79 per cent equity stake in Nutritionalab Pvt Ltd, which owns "Wellbeing Nutrition", according to a joint statement. This includes 35 per cent from the founder Avnish Chhabria and 44 per cent from existing shareholders. Its investors -- Early backers Fireside Ventures and Hindustan Unilever -- will divest their collective 40 per cent stake. This Rs 1,583 crores all-cash transaction represents the largest exit in India's health and wellness startup space to date, it added. This strategic expansion of USV, a leading player in diabetes and cardiac care, into consumer wellness is aligned with its expansion across the healthcare continuum. "The addition of Wellbeing Nutrition reinforces USV's evolution into a comprehensive healthcare powerhouse spanning both therapeutic excellence and consumer ...

Medtech manufacturing industry divided on policy for refurbished devices

Domestic device makers warn of safety and dumping risks, while MNC bodies back affordability benefits as the Centre reviews policy on refurbished high-end medical device imports

Zydus Lifesciences Q3 net profit rises 9% on strong US and India growth

Zydus Lifesciences posted higher Q3 profit and revenue, aided by strong growth in the US and India businesses, improved margins, and steady momentum in generics, specialty and chronic segments

Centre mandates drug cos to submit post-approval changes for new drugs

Draft amendment seeks mandatory reporting of manufacturing and quality changes to drug regulator

Health-tech startup Tata 1mg eyes 500 offline stores by year-end

The move signals a sharper push towards omnichannel growth amid continued regulatory uncertainty in e-pharmacy